site stats

Irs2 cancer

WebSynonyms [ 1] IRS-2. Insulin receptor substrate 2 (IRS2) is a gene that encodes a protein of the same name that functions in regulating the effects of insulin-like growth factor 1 and insulin by mediating signaling between receptor tyrosine kinases and other associated … WebMay 1, 2016 · In the last years, many studies have indicated that IRS2 participates in the regulation of important biological processes involved in cancer phenotype, including cell proliferation, clonogenicity, metabolism and survival. The present review contains data on …

Abstract 266: Adaptation of colorectal cancer cells to the brain ...

WebApr 9, 2024 · Insulin receptor substrate 2 (IRS2) belongs to the member of IRS family that regulates cell proliferation, apoptosis, and metabolism by functioning as a molecular adaptor to integrate and coordinate extracellular signals from insulin and other ligands to mitochondria (Dearth et al. 2007 ). WebMechanistically, insulin receptor substrate 2 (IRS2) was identified as a direct target of miR‑766 in PTC cells. IRS2 was upregulated in PTC tissues, and this was inversely correlated with miR‑766 expression. Inhibition of IRS2 simulated the tumor suppressor activity of … chizacos food truck https://multiagro.org

IRS2 (insulin receptor substrate 2) - atlasgeneticsoncology.org

WebJun 15, 2024 · IRS2 is a cytoplasmic adaptor mediating effects of insulin and IGF-1 receptors and is involved in more aggressive behavior of different cancer types. In agreement with the genomic data, immunohistochemistry of human clinical samples showed increased expression of IRS2 protein in BM. WebMar 4, 2024 · In addition, it was found that IRS2 silencing had an inhibitory effect on the progression of NSCLC, and the upregulation of IRS2 partially impaired the inhibitory effect of miR‐448 in NSCLC. WebIRS2 - Explore an overview of IRS2, with a histogram displaying coding mutations, full tabulated details of all associated variants, tissue distribution and any drug resistance data. Projects COSMIC grasslands wholesale

Abstract 2854: Adaptation of colorectal cancer cells to the brain ...

Category:IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer

Tags:Irs2 cancer

Irs2 cancer

IRS2 (insulin receptor substrate 2) - atlasgeneticsoncology.org

WebApr 19, 2024 · The identification of somatic mutations in IRS2 in 29% of PILC samples is the first report of recurrent IRS2 mutation in any subtype of breast cancer to our knowledge. IRS2 is an adaptor protein for the insulin and IGF-1 receptors, and it mediates their … WebMar 29, 2024 · This gene encodes the insulin receptor substrate 2, a cytoplasmic signaling molecule that mediates effects of insulin, insulin-like growth factor 1, and other cytokines by acting as a molecular adaptor between diverse receptor tyrosine kinases and …

Irs2 cancer

Did you know?

WebDec 3, 2015 · 2 Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science ... harbored a mutation in the insulin receptor substrate 2 (IRS2) gene. IRS2 belongs to the IRS family of cytoplasmic adaptor proteins that function as essential signaling intermediates for intracellular signaling pathways to modulate normal … http://www.cancerindex.org/geneweb/IRS2.htm

WebThe IRS2 GD genotype reduced risk of colon cancer, except among those with an IRS1 R allele. No significant associations were seen in analyses of main effects or interactions of these variants and rectal cancer risk. Conclusions: Both IRS1 and IRS2 variants were associated with colon cancer risk independently. WebJul 7, 2013 · IRS2 is associated with cancer cell motility and metastasis. Currently there are no anti-cancer agents that target IRS1/2. We present new IGF1R/IRS-targeted agents (NT compounds) that promote inhibitory Ser-phosphorylation and degradation of IRS1 and IRS2.

WebMay 1, 2016 · Jackson and colleagues (Jackson, et al. 1998) observed that IRS2 is widely expressed in breast cancer cell lines and primary breast cancer cells. In breast cancer patients, membrane localization of IRS-2 was associated with reduced overall survival by multivariate analysis (Clark, et al. 2011). WebApr 19, 2024 · IRS2 mutations identified in PILC enhance invasion, revealing a role for this signaling adaptor in the aggressive nature of PILC. Invasive breast cancer is a heterogenous disease, with the majority of tumors diagnosed as either invasive ductal carcinoma (IDC; ~80%) or invasive lobular carcinoma (ILC; ~8–14%).

WebMar 18, 2024 · Breast cancers that do not express the estrogen receptor (ER) or the progesterone receptor (PR) and have no ERBB2 (commonly referred to as human epidermal growth factor receptor 2 [HER2]) amplification are categorized as triple-negative breast cancers (TNBCs) and comprise 10%–20% of all breast cancers ( Dent et al., 2007, …

WebThe IR of any CVC-related complication was numerically higher in patients with SBS with cancer vs without cancer (3.44 vs 1.86 cases per 1,000 catheter-days, respectively). Conclusion: Our study quantifies the incidence of complications in patients with CVCs, including those with SBS, in Japan. Keywords: database, epidemiology, prevalence ... grassland sweet cream salted butterWebApr 2, 2024 · These results indicate that Irs1 and Irs2 are required for Kras -driven lung tumor initiation and that Kras -transformed cells can eventually bypass Irs1 / Irs2 loss, developing more aggressive tumors at a highly variable and extended latency. Fig. 1. Loss of Irs1 and Irs2 significantly delays Kras -driven lung tumorigenesis. grasslands weather saskatchewanWebJan 9, 2024 · To investigate the clinical implications of IRS2 gain/amplification in cancer progression, we analyzed the SCLC dataset that is publicly available via the cBioPortal for Cancer Genomics (http://www.cbioportal.org/msk-impact). IRS2 amplification was … grasslands wildlife refugeWebAccording to Porter et al. (2013), IRS2 levels are low in the early form of breast cancer DCIS (ductal carcinoma in situ) but high in invasive breast cancers and associated with reduced survival. In contrast, IRS1 is expressed at comparable levels in both invasive breast … chiz and ex wifeWebJan 9, 2024 · Small cell lung cancer (SCLC) is a fast-growing and malignant cancer that responds well to chemotherapy; however, the survival rate is less than 15% after 2 years of diagnosis. Therefore, novel therapeutic agents for treating SCLC patients need to be evaluated. This study aims to identify the therapeutic targets based on the comprehensive … chiza insectoWebApr 11, 2024 · The mission of the Public Health Genomics is to integrate advances in human genetics into public health research, policy, and programs grasslands wildlife trustWebJan 24, 2024 · Recent data indicate that IGF1R/IRS signaling is a potential therapeutic target in BCR-ABL1-negative myeloproliferative neoplasms (MPN); in this pathway, IRS2 is involved in the malignant ... chiz and chic